Neuropsychopharmacology Reports最新文献_第9页

Changes in suicidal ideation during treatment among patients with major depressive disorder: A 6-month naturalistic follow-up study. 重度抑郁障碍患者在治疗期间自杀意念的变化：为期 6 个月的自然追踪研究。

IF 2.5

Neuropsychopharmacology Reports Pub Date : 2024-06-01 Epub Date: 2024-03-05 DOI: 10.1002/npr2.12428

Aoi Sato, Norio Sugawara, Yasushi Kawamata, Norio Yasui-Furukori

{"title":"Changes in suicidal ideation during treatment among patients with major depressive disorder: A 6-month naturalistic follow-up study.","authors":"Aoi Sato, Norio Sugawara, Yasushi Kawamata, Norio Yasui-Furukori","doi":"10.1002/npr2.12428","DOIUrl":"10.1002/npr2.12428","url":null,"abstract":"Aim: There is limited evidence regarding predictors of changes in suicidal ideation (SI) in patients with major depressive disorder (MDD). The objective of this study was to describe changes in SI over a 6-month period and identify their predictors from naturalistic observations of MDD patients.Methods: In the cross-sectional analysis, we examined 257 patients with MDD at the first-visit assessment. Among the patients, 119 who completed the 6-month assessment (completers) were included in the longitudinal analysis. For the evaluation of depressive symptoms, including SI, the Quick Inventory of Depressive Symptomatology-Japanese version was administered at both the first-visit and follow-up assessments. At baseline, we also administered the Japanese version of the Ten Item Personality Inventory to assess personality traits and the PRIME Screen-Revised to assess psychotic symptoms.Results: In the cross-sectional analysis of first-visit patients, 36.2% (93/257) exhibited SI. Among completers, 14.3% (17/119) had prolonged SI. Among the completers with SI at the first-visit assessment, 38.6% (17/44) had SI at the follow-up assessment (prolonged SI). In linear regression models including all completers, prolonged SI was positively associated with endorsement of suspiciousness/persecutory ideas and negatively associated with higher age.Conclusion: More than one-third of completers who had SI at the first-visit assessment experienced prolonged SI (SI at follow-up). Our findings can help clinicians predict the course of MDD by identifying associated demographic and clinical characteristics.","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"371-380"},"PeriodicalIF":2.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11144608/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140039918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of the 12-item and 36-item versions of the World Health Organization Disability Assessment Schedule (WHODAS) 2.0 using longitudinal data from community mental health outreach service users. 利用社区精神健康外展服务使用者的纵向数据，比较世界卫生组织残疾评估表（WHODAS）2.0 的 12 项和 36 项版本。

IF 2.5

Neuropsychopharmacology Reports Pub Date : 2024-06-01 Epub Date: 2024-03-11 DOI: 10.1002/npr2.12426

Mai Iwanaga, Sosei Yamaguchi, Sayaka Sato, Kaori Usui, Kiyoaki Nakanishi, Erisa Nishiuchi, Michiyo Shimodaira, Yugan So, Chiyo Fujii

{"title":"Comparison of the 12-item and 36-item versions of the World Health Organization Disability Assessment Schedule (WHODAS) 2.0 using longitudinal data from community mental health outreach service users.","authors":"Mai Iwanaga, Sosei Yamaguchi, Sayaka Sato, Kaori Usui, Kiyoaki Nakanishi, Erisa Nishiuchi, Michiyo Shimodaira, Yugan So, Chiyo Fujii","doi":"10.1002/npr2.12426","DOIUrl":"10.1002/npr2.12426","url":null,"abstract":"Aim: This study aimed to compare the 12-item and 36-item versions of the World Health Organization Disability Assessment Schedule (WHODAS) 2.0 using longitudinal data from community mental health outreach service users.Methods: Using data from Tokorozawa City mental health outreach service users in Japan, total and domain WHODAS-12 and WHODAS-36 scores were compared. First, we examined score-change differences by domain at the start of outreach services (T1) and 1 year later (T2) for each version. Next, we compared differences between the two versions using Pearson's correlation, Wilcoxon signed-rank test, and Bland-Altman analysis.Results: Among 20 participants, total scores and scores of some domains (i.e., cognition, getting along, life activities, and participation) were significantly lower at T2 than at T1 on both versions (p < 0.010). WHODAS-36 scores were significantly lower at T2 than at T1 for the self-care domain (p = 0.018). Except for self-care, strong correlations were found between scores from the two versions (p < 0.001). In the Wilcoxon signed-rank test and Bland-Altman analysis, we found significant differences between the scores of the two versions in the mobility, self-care, and participation domains. There were no significant differences in the distribution or systematic errors between the two versions in scores for the other domains or total score.Conclusion: We found strong positive correlations between WHODAS-12 and WHODAS-36 total scores with no statistical differences between them. For some domains, differences in distribution and systematic errors were found.","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"457-463"},"PeriodicalIF":2.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11144613/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140102131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Quantification of cytosine modifications in the aged mouse brain. 衰老小鼠脑内胞嘧啶修饰的定量分析。

IF 2.5

Neuropsychopharmacology Reports Pub Date : 2024-03-01 Epub Date: 2023-12-06 DOI: 10.1002/npr2.12396

Hiroko Sugawara, Akitoshi Date, Satoshi Fuke, Yutaka Nakachi, Tadafumi Kato, Minoru Narita, Miki Bundo, Kazuya Iwamoto

{"title":"Quantification of cytosine modifications in the aged mouse brain.","authors":"Hiroko Sugawara, Akitoshi Date, Satoshi Fuke, Yutaka Nakachi, Tadafumi Kato, Minoru Narita, Miki Bundo, Kazuya Iwamoto","doi":"10.1002/npr2.12396","DOIUrl":"10.1002/npr2.12396","url":null,"abstract":"Quantifying cytosine modifications in various brain regions provides important insights into the gene expression regulation and pathophysiology of neuropsychiatric disorders. In this study, we quantified 5-methylcytosine (5-mC), 5-hydroxymethylation (5-hmC), and 5-formylcytosine (5-fC) levels in five brain regions (the frontal lobe, cerebral cortical region without frontal lobe, hippocampus, basal ganglia, and the cerebellum) and the heart at three developmental periods (12, 48, and 101 weeks). We observed significant regional variations in cytosine modification. Notably, regional variations were generally maintained throughout development, suggesting that epigenetic regulation is unique to each brain region and remains relatively stable with age. The 5-mC and 5-hmC levels were positively correlated, although the extent of the correlations seemed to differ in different brain regions. On the contrary, 5-fC levels did not correlate with 5-mC or 5-hmC levels. Additionally, we observed an age-dependent decrease in 5-fC levels in the basal ganglia, suggesting a unique epigenetic regulation mechanism. Further high-resolution studies using animal models of neuropsychiatric disorders as well as postmortem brain evaluation are warranted.","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"250-255"},"PeriodicalIF":2.5,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10932792/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138499005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-acting injectable antipsychotics as maintenance therapy for schizophrenia during the COVID-19 pandemic: A micro-narrative review. 在 COVID-19 大流行期间，长效注射用抗精神病药物作为精神分裂症的维持疗法：微观叙事回顾。

IF 2.5

Neuropsychopharmacology Reports Pub Date : 2024-03-01 Epub Date: 2024-01-06 DOI: 10.1002/npr2.12413

Yoshiyo Oguchi, Nobumi Miyake, Kumiko Ando

{"title":"Long-acting injectable antipsychotics as maintenance therapy for schizophrenia during the COVID-19 pandemic: A micro-narrative review.","authors":"Yoshiyo Oguchi, Nobumi Miyake, Kumiko Ando","doi":"10.1002/npr2.12413","DOIUrl":"10.1002/npr2.12413","url":null,"abstract":"The coronavirus disease pandemic has presented healthcare systems with unprecedented challenges globally and substantially impacted the management of chronic diseases such as schizophrenia. This narrative review highlights the usefulness of long-acting injectable antipsychotics (LAIs) as maintenance therapy for patients with schizophrenia during the pandemic. The analysis of relevant literature and psychiatric survey data revealed diverse trends in LAIs prescription and patient adherence with oral antipsychotics. Although some studies have reported a decrease in LAIs prescriptions owing to pandemic-related disruptions, others have suggested stable patient adherence with oral antipsychotics. Approximately 70% of Japanese psychiatrists reported an increase in schizophrenia relapse rates in a survey, underscoring the critical role of LAIs in maintaining therapeutic stability. The potential benefits of LAIs with extended dosing intervals have been highlighted, including improving oral medication adherence and reducing the frequency of hospital visits. In conclusion, this review emphasizes the continued need for uninterrupted LAIs therapy in conjunction with community and home-based care despite the disruptions caused by the coronavirus disease pandemic. Further development of LAIs maintenance therapy strategies considering the ongoing pandemic and potential future public health emergencies are required.","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"34-41"},"PeriodicalIF":2.5,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10932768/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139111110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A multicenter, single-arm, open-label interventional study of adherence to brexpiprazole during switching from previous antipsychotic drugs in patients with schizophrenia or schizoaffective disorder. 一项多中心、单臂、开放标签的干预性研究，旨在了解精神分裂症或情感分裂症患者从既往的抗精神病药物转用布来匹唑期间的依从性。

IF 2.5

Neuropsychopharmacology Reports Pub Date : 2024-03-01 Epub Date: 2024-01-22 DOI: 10.1002/npr2.12416

Kazuyuki Nakagome, Hisateru Tachimori, Shiro Endo, Ken Murakami, Takaharu Azekawa, Seiji Hongo, Kazunari Niidome, Yoshitsugu Kojima, Sakiko Yamada, Hideki Oi, Tomiki Sumiyoshi

{"title":"A multicenter, single-arm, open-label interventional study of adherence to brexpiprazole during switching from previous antipsychotic drugs in patients with schizophrenia or schizoaffective disorder.","authors":"Kazuyuki Nakagome, Hisateru Tachimori, Shiro Endo, Ken Murakami, Takaharu Azekawa, Seiji Hongo, Kazunari Niidome, Yoshitsugu Kojima, Sakiko Yamada, Hideki Oi, Tomiki Sumiyoshi","doi":"10.1002/npr2.12416","DOIUrl":"10.1002/npr2.12416","url":null,"abstract":"The rate of medication persistence was examined in patients with schizophrenia or schizoaffective disorder during switching from previously administered antipsychotics to brexpiprazole, a new dopamine D2 receptor partial agonist. A multicenter, single-arm, open-label 24-week interventional study was conducted, consisting of two 12-week consecutive periods: an initial switch (by plateau cross-titration) with the subsequent period, followed by a second maintenance period. Prior antipsychotics were olanzapine or risperidone/paliperidone. The primary and secondary outcome measures were medication persistence rates after the first 12 weeks and changes from baseline in the Specific Levels of Functioning Scale (SLOF), Subjective Well-being under Neuroleptic drug treatment Short form (SWNS), and Positive and Negative Syndrome Scale (PANSS) scores, respectively. In total, 79 patients were administered brexpiprazole and the medication persistence rate at 12 weeks was 78.5%, which was significantly higher than the predefined threshold of 65%. Regarding the prior medication, the persistence rate at 12 weeks was 84.6% for olanzapine and 72.5% for risperidone/paliperidone. Significant improvements from baseline were observed in the SLOF, SWNS, and PANSS scores. There were no adverse events of concern. Thus, brexpiprazole appeared to be a suitable antipsychotic on switching from olanzapine, risperidone, or paliperidone.","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"187-196"},"PeriodicalIF":2.5,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10932803/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139521685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gaze measurements during viewing human dialogue scenes in adults with ADHD: Preliminary findings. 成人ADHD患者在观看人类对话场景时的凝视测量:初步发现。

IF 2.5

Neuropsychopharmacology Reports Pub Date : 2024-03-01 Epub Date: 2023-12-04 DOI: 10.1002/npr2.12383

Yuta Nagatsuka, Dan Nakamura, Marie Ota, Gosuke Arai, Yuriko Iwami, Hirohisa Suzuki, Akisa Tomita, Yoichi Hanawa, Wakaho Hayashi, Akira Iwanami

{"title":"Gaze measurements during viewing human dialogue scenes in adults with ADHD: Preliminary findings.","authors":"Yuta Nagatsuka, Dan Nakamura, Marie Ota, Gosuke Arai, Yuriko Iwami, Hirohisa Suzuki, Akisa Tomita, Yoichi Hanawa, Wakaho Hayashi, Akira Iwanami","doi":"10.1002/npr2.12383","DOIUrl":"10.1002/npr2.12383","url":null,"abstract":"Aim: Eye gaze measurement to human dialogue scenes in adults with attention deficit hyperactivity disorder (ADHD) was investigated. We examined whether eye gaze measurement might be a biological marker of ADHD.Methods: Twenty-two individuals with ADHD (mean age, 34.5 years) attending the outpatient clinic of Showa University Karasuyama Hospital were included in the study, and 26 healthy individuals (mean age, 32.6 years) with no history of mental disorders were used as the control group. For the participants, intellectual functioning was estimated using the Japanese Adult Reading Test, and mental symptoms were assessed using the Autism Spectrum Quotient and Conner's Adult ADHD Rating Scale. We extracted human dialogue scenes from two classic movies as visual stimuli and recorded the participant's gaze while watching these scenes using Tobii's eye tracker.Results: For gazing time, repeated measures analysis of variance showed no significant main effect of \"group\" and no significant interaction effect between \"group\" and areas of interest \"(AOI).\" In the normal group, gazing time at the eyes was significantly longer than those at the mouth, body, and background; in the ADHD group, gazing time at the eyes was significantly longer than only that at the background.Conclusion: Given the different results obtained in the past in ASD, these results suggest that it would be necessary to directly compare the two groups to determine whether the gaze measurement shows significant differences in ASD and ADHD.","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"73-79"},"PeriodicalIF":2.5,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10932770/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138482758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of bilateral repetitive transcranial magnetic stimulation on prospective memory in patients with schizophrenia: A double-blind randomized controlled clinical trial. 双侧重复经颅磁刺激对精神分裂症患者前瞻性记忆的影响：双盲随机对照临床试验。

IF 2.5

Neuropsychopharmacology Reports Pub Date : 2024-03-01 Epub Date: 2023-12-06 DOI: 10.1002/npr2.12397

Fen Xue, Xin-Fu Wang, Fan-Ni Kong, Tian-Lu Yin, Yu-Hong Wang, Li-Da Shi, Xiao-Wen Liu, Hui-Jing Yu, Li-Jun Liu, Ping Zhu, Xiao-Xue Qi, Xue-Jing Xu, Hong-Pu Hu, Su-Xia Li

{"title":"Effects of bilateral repetitive transcranial magnetic stimulation on prospective memory in patients with schizophrenia: A double-blind randomized controlled clinical trial.","authors":"Fen Xue, Xin-Fu Wang, Fan-Ni Kong, Tian-Lu Yin, Yu-Hong Wang, Li-Da Shi, Xiao-Wen Liu, Hui-Jing Yu, Li-Jun Liu, Ping Zhu, Xiao-Xue Qi, Xue-Jing Xu, Hong-Pu Hu, Su-Xia Li","doi":"10.1002/npr2.12397","DOIUrl":"10.1002/npr2.12397","url":null,"abstract":"Aims: To investigate effects of repetitive transcranial magnetic stimulation (rTMS) on the prospective memory (PM) in patients with schizophrenia (SCZ).Methods: Fifty of 71 patients completed this double-blind placebo-controlled randomized trial and compared with 18 healthy controls' (HCs) PM outcomes. Bilateral 20 Hz rTMS to the dorsolateral prefrontal cortex at 90% RMT administered 5 weekdays for 4 weeks for a total of 20 treatments. The Positive and Negative Symptom Scale (PANSS), the Scale for the Assessment of Negative Symptoms (SANS), and PM test were assessed before and after treatment.Results: Both Event-based PM (EBPM) and Time-based PM (TBPM) scores at baseline were significantly lower in patients with SCZ than that in HCs. After rTMS treatments, the scores of EBPM in patients with SCZ was significantly improved and had no differences from that in HCs, while the scores of TBPM did not improved. The negative symptom scores on PANSS and the scores of almost all subscales and total scores of SANS were significantly improved in both groups.Conclusions: Our findings indicated that bilateral high-frequency rTMS treatment can alleviate EBPM but not TBPM in patients with SCZ, as well as improve the negative symptoms.Significance: Our results provide one therapeutic option for PM in patients with SCZ.","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"97-108"},"PeriodicalIF":2.5,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10932802/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138488052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Practical clinical guidelines and pharmacological treatment for attention-deficit hyperactivity disorder in Asia. 亚洲注意缺陷多动障碍的实用临床指南和药物治疗。

IF 2.5

Neuropsychopharmacology Reports Pub Date : 2024-03-01 Epub Date: 2023-12-07 DOI: 10.1002/npr2.12381

Kentaro Kawabe, Fumie Horiuchi, Yu Matsumoto, Saori Inoue, Maya Okazawa, Rie Hosokawa, Kiwamu Nakachi, Junya Soga, Shu-Ichi Ueno

{"title":"Practical clinical guidelines and pharmacological treatment for attention-deficit hyperactivity disorder in Asia.","authors":"Kentaro Kawabe, Fumie Horiuchi, Yu Matsumoto, Saori Inoue, Maya Okazawa, Rie Hosokawa, Kiwamu Nakachi, Junya Soga, Shu-Ichi Ueno","doi":"10.1002/npr2.12381","DOIUrl":"10.1002/npr2.12381","url":null,"abstract":"Attention-deficit hyperactivity disorder (ADHD) is characterized by persistent symptoms of inattention, hyperactivity, and impulsivity. Both, stimulant and nonstimulant medications have been approved for the treatment of this disorder. Several Western guidelines recommend the use of prescribed Food and Drug Administration (FDA)-approved medications for ADHD along with parental training in behavior management and behavioral classroom intervention. In 2022, new Japanese guidelines for ADHD were issued, which recommended school environment management and psychosocial treatment as the first-line treatment, with pharmacological treatment added as the second-line treatment. Although Japanese guidelines, including pharmacological treatments, have been established, the guidelines and utilization of ADHD medications across Asian regions are unclear. Therefore, to appropriately evaluate the strategy of pharmacological treatments for ADHD, we investigated Asian regional guidelines for ADHD medication in children. We also reviewed the guidelines in Malaysia, Singapore, India, and the Republic of Korea and found that these guidelines differ from Western guidelines.","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"29-33"},"PeriodicalIF":2.5,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10932761/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138499004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of brexpiprazole, aripiprazole, and placebo for Japanese major depressive disorder: A systematic review and network meta-analysis. 比较布雷克哌唑、阿立哌唑和安慰剂对日本重度抑郁障碍的治疗效果：系统综述和网络荟萃分析。

IF 2.5

Neuropsychopharmacology Reports Pub Date : 2024-03-01 Epub Date: 2024-01-14 DOI: 10.1002/npr2.12414

Taro Kishi, Kenji Sakuma, Takeo Saito, Atsuo Nakagawa, Masaki Kato, Nakao Iwata

{"title":"Comparison of brexpiprazole, aripiprazole, and placebo for Japanese major depressive disorder: A systematic review and network meta-analysis.","authors":"Taro Kishi, Kenji Sakuma, Takeo Saito, Atsuo Nakagawa, Masaki Kato, Nakao Iwata","doi":"10.1002/npr2.12414","DOIUrl":"10.1002/npr2.12414","url":null,"abstract":"Aim: This systematic review and frequentist network meta-analysis used random-effects models is conducted to determine whether there are differences in the efficacy, acceptability, tolerability, and safety profiles of brexpiprazole (BRE) and aripiprazole (ARI) for Japanese with major depressive disorder (MDD) who were inadequately responsive to antidepressants.Methods: Outcome measures were scores on the Montgomery Åsberg Depression Rating Scale (primary), the Clinical Global Impression severity scale, and social functioning scale; the non-response rate; the non-remission rate; all-cause discontinuation; discontinuation due to adverse events (DAE); at least one adverse event (1AE); serious adverse event, akathisia; tremor; weight gain.Results: A literature search identified three double-blind, randomized, placebo-controlled trials. These comprised one BRE study (with a 1 mg/day [BRE1] and a 2 mg/day [BRE2]) and two ARI studies (with a 3 mg/day arm and a flexible-dose arm[within the dosage range approved in Japan]) (n = 1736). Both BRE and ARI demonstrated better efficacy than the placebo. BRE but not ARI had a higher DAE than the placebo. ARI but not BRE had a higher 1AE than the placebo. BRE and ARI had a higher risk of akathisia and weight gain than the placebo. There were no significant differences between BRE and ARI for any of the outcomes. Although BRE1 had good efficacy, it carried risk of weight gain. Although BRE2 also had efficacy, it carried risks of DAE, akathisia, and weight gain. However, the risk of akathisia in BRE2 was reduced by an initial dose of 0.5 mg/day rather than 1.0 mg/day.Conclusions: Overall BRE showed similar utility to ARI and a good risk-benefit balance.","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"165-175"},"PeriodicalIF":2.5,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10932760/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139466853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A descriptive analysis of spontaneous reports of antipsychotic-induced tardive dyskinesia and other extrapyramidal symptoms in the Japanese Adverse Drug Event Report database. 日本药物不良事件报告数据库中抗精神病药物诱导的迟发性运动障碍和其他锥体外系症状的自发报告的描述性分析。

IF 2.5

Neuropsychopharmacology Reports Pub Date : 2024-03-01 Epub Date: 2023-10-26 DOI: 10.1002/npr2.12385

Yosuke Saga, Chih-Lin Chiang, Akihide Wakamatsu

{"title":"A descriptive analysis of spontaneous reports of antipsychotic-induced tardive dyskinesia and other extrapyramidal symptoms in the Japanese Adverse Drug Event Report database.","authors":"Yosuke Saga, Chih-Lin Chiang, Akihide Wakamatsu","doi":"10.1002/npr2.12385","DOIUrl":"10.1002/npr2.12385","url":null,"abstract":"AimThe aim of this study is to summarize the spontaneous reports of tardive dyskinesia (TD) and extrapyramidal symptoms (EPSs) that occurred in Japan over the past decade. MethodsThe study analyzed TD and EPS cases reported in the Japanese Adverse Drug Event Report database between April 2011 and March 2021. The cases were stratified by the diagnoses of schizophrenia, bipolar disorders, and depressive disorders. ResultsIn total, 800 patients including a total of 171 TD cases and 682 EPS cases were reported in the JADER database across psychiatric diagnosis. The cases were caused by first-generation antipsychotics (FGA, TD: n = 105, EPS: n = 245) and second-generation antipsychotics (SGA, TD: n = 144, EPS: n = 598). The SGA were categorized based on Neuroscience-based Nomenclature (NbN) regarding pharmacological domain and mode of action, which were reported evenly as the offending agents. Among reported treatment and outcome in TD cases (n = 67, 37.6%) and EPS cases (n = 405, 59.3%), the relatively limited number of TD cases were reported as recovered/improved was also limited (n = 32, 47.8%) compared to those of EPS cases (n = 266, 65.7%). Some cases still had residual symptoms or did not recover fully (TD: n = 21, 31.3%, EPS: n = 77, 19.0%). CONCLUSION: Tardive dyskinesia and EPS have been widely reported in Japan over the past decade across psychiatric diagnoses and antipsychotic classes. LIMITATIONS: It is important to acknowledge the presence of reporting bias and the lack of comparators to accurately assess risks. Owing to the nature of spontaneous reporting, the estimation of prevalence is not feasible.","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":" ","pages":"221-226"},"PeriodicalIF":2.5,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10932779/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54230323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0